+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-04-15Number of Pages: 65

Nonalcoholic Steatohepatitis Therapeutics Market (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025

Table of Contents

Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
1.4 Assumptions

Chapter 2 Executive Summary
2.1 Global NASH Market, by Drug, 2025 (US$ Mn)

Chapter 3 Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market Overview 
3.1 Introduction
3.2 Epidemiology of Nonalcoholic Steatohepatitis (Qualitative Analysis)
     3.2.1 North America
     3.2.2 Europe
     3.2.3 Asia Pacific
     3.2.4 Rest of World
3.3 Diagnosis and Treatment of NASH (Qualitative Analysis)
3.4 Market Dynamics
     3.4.1 Drivers
     3.4.2 Restraints
     3.4.3 Opportunities

Chapter 4 Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type, 2015 – 2025 (US$ Mn)
4.1 Overview
4.2 Potential Drug Candidates in Phase III
     4.2.1 Obeticholic Acid (OCA)
     4.2.2 Aramchol (arachidyl amido cholanoic acid)
     4.2.3 Saroglitazar
     4.2.4 Elafibranor
4.3 Pipeline Analysis
     4.3.1 Tabular Representation of Phase I and Phase II Clinical Trials (Qualitative Analysis)
4.4 Target Population By Geography: NASH Market 

Chapter 5 Recommendations

Chapter 6 Company Profiles
6.1 AstraZeneca plc
     6.1.1 Company Overview
     6.1.2 Financial Overview
     6.1.3 Product Pipeline
     6.1.4 Business Strategies
     6.1.5 Recent Developments
6.2 Intercept Pharmaceuticals Inc.
6.3 Galmed Pharmaceuticals
6.4 GENFIT SA 
6.5 Gilead Sciences Inc. 
6.6 Zydus Cadila 
6.7 Immuron Ltd. 
6.8 Conatus Pharmaceuticals 
6.9 Tobira Therapeutics Inc.
6.10 Others


 
 
Back To Top